How does fampridine affect upper limb function in Multiple Sclerosis?

多发性硬化症(MS)是一种常见的致残神经系统疾病，影响着数以千计的澳大利亚年轻人。2011年，法普利定获得了TGA批准，用于治疗多发性硬化症的步行障碍，但其作用机制尚不清楚，其对除下肢功能以外的其他领域的影响仍未得到测试。我们的研究将测试法普利丁是否能改善多发性硬化症患者的上肢损害，并将使用中枢神经系统传导的电生理指标来揭示其作用机制。

Multiple sclerosis (MS) is a common and disabling neurological disease affecting thousands of young Australians. In 2011 Fampridine received TGA approval for walking impairment in MS, but its mechanism of action is unknown and its effects on domains other than lower limb function remain untested. Our study will test whether Fampridine improves upper limb impairment in MS patients and will use electrophysiological measures of central nervous system conduction to uncover its mechanism of action.